Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks
Background Nitroglycerin administration allows the study of cluster headache attacks in their entirety in a standardised way. Methods A single-blind, placebo-controlled, cross-over study using weight-calculated intravenous nitroglycerin administration at 0.5 µg/kg/min over 20 minutes to study cluste...
Saved in:
Published in | Cephalalgia Vol. 41; no. 8; pp. 913 - 933 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
London, England
SAGE Publications
01.07.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 0333-1024 1468-2982 1468-2982 |
DOI | 10.1177/0333102421989617 |
Cover
Loading…
Abstract | Background
Nitroglycerin administration allows the study of cluster headache attacks in their entirety in a standardised way.
Methods
A single-blind, placebo-controlled, cross-over study using weight-calculated intravenous nitroglycerin administration at 0.5 µg/kg/min over 20 minutes to study cluster headache attacks, including accompanying non-headache symptoms and cranial autonomic symptoms.
Results
Thirty-three subjects with cluster headache were included in the study; 24 completed all three study visits. Nitroglycerin-induced attacks developed in 26 out of 33 subjects (79%) receiving unblinded nitroglycerin infusion, and in 19 out of 25 subjects (76%) receiving single-blinded nitroglycerin infusion, compared with one out of 24 subjects (4%) receiving single-blinded placebo infusion. Episodic cluster headache subjects had a shorter latency period to a nitroglycerin-induced attack compared to the chronic cluster headache (CCH) subjects (U = 15, z = −2.399, p = 0.016). Sixteen of nineteen episodic cluster headache (mean, 84%; 95% confidence interval, 66–100%) and 11 of 14 chronic cluster headache subjects developed a nitroglycerin-induced attack (79%, 54–100%) following the unblinded nitroglycerin infusion. Following the single-blinded nitroglycerin infusion, eight out of 13 episodic cluster headache (62%, 31–92%) and 11 out of 12 chronic cluster headache (92%, 73–100%) subjects developed nitroglycerin-induced attacks. Nitroglycerin induced non-headache symptoms in the majority of subjects receiving it: 91% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visits, compared with 33% in the single-blinded placebo visit. Cranial autonomic symptoms were induced by nitroglycerin infusion, 94% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visit, compared with 17% in the single-blinded placebo visit.
Conclusion
Intravenous weight-adjusted nitroglycerin administration in both episodic cluster headache in bout and chronic cluster headache is effective and reliable in inducing cluster headache attacks, cranial autonomic symptoms and non-headache symptoms. |
---|---|
AbstractList | Nitroglycerin administration allows the study of cluster headache attacks in their entirety in a standardised way.
A single-blind, placebo-controlled, cross-over study using weight-calculated intravenous nitroglycerin administration at 0.5 µg/kg/min over 20 minutes to study cluster headache attacks, including accompanying non-headache symptoms and cranial autonomic symptoms.
Thirty-three subjects with cluster headache were included in the study; 24 completed all three study visits. Nitroglycerin-induced attacks developed in 26 out of 33 subjects (79%) receiving unblinded nitroglycerin infusion, and in 19 out of 25 subjects (76%) receiving single-blinded nitroglycerin infusion, compared with one out of 24 subjects (4%) receiving single-blinded placebo infusion. Episodic cluster headache subjects had a shorter latency period to a nitroglycerin-induced attack compared to the chronic cluster headache (CCH) subjects (
= 15, z = -2.399,
= 0.016). Sixteen of nineteen episodic cluster headache (mean, 84%; 95% confidence interval, 66-100%) and 11 of 14 chronic cluster headache subjects developed a nitroglycerin-induced attack (79%, 54-100%) following the unblinded nitroglycerin infusion. Following the single-blinded nitroglycerin infusion, eight out of 13 episodic cluster headache (62%, 31-92%) and 11 out of 12 chronic cluster headache (92%, 73-100%) subjects developed nitroglycerin-induced attacks. Nitroglycerin induced non-headache symptoms in the majority of subjects receiving it: 91% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visits, compared with 33% in the single-blinded placebo visit. Cranial autonomic symptoms were induced by nitroglycerin infusion, 94% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visit, compared with 17% in the single-blinded placebo visit.
Intravenous weight-adjusted nitroglycerin administration in both episodic cluster headache in bout and chronic cluster headache is effective and reliable in inducing cluster headache attacks, cranial autonomic symptoms and non-headache symptoms. Background Nitroglycerin administration allows the study of cluster headache attacks in their entirety in a standardised way. Methods A single-blind, placebo-controlled, cross-over study using weight-calculated intravenous nitroglycerin administration at 0.5 µg/kg/min over 20 minutes to study cluster headache attacks, including accompanying non-headache symptoms and cranial autonomic symptoms. Results Thirty-three subjects with cluster headache were included in the study; 24 completed all three study visits. Nitroglycerin-induced attacks developed in 26 out of 33 subjects (79%) receiving unblinded nitroglycerin infusion, and in 19 out of 25 subjects (76%) receiving single-blinded nitroglycerin infusion, compared with one out of 24 subjects (4%) receiving single-blinded placebo infusion. Episodic cluster headache subjects had a shorter latency period to a nitroglycerin-induced attack compared to the chronic cluster headache (CCH) subjects (U = 15, z = −2.399, p = 0.016). Sixteen of nineteen episodic cluster headache (mean, 84%; 95% confidence interval, 66–100%) and 11 of 14 chronic cluster headache subjects developed a nitroglycerin-induced attack (79%, 54–100%) following the unblinded nitroglycerin infusion. Following the single-blinded nitroglycerin infusion, eight out of 13 episodic cluster headache (62%, 31–92%) and 11 out of 12 chronic cluster headache (92%, 73–100%) subjects developed nitroglycerin-induced attacks. Nitroglycerin induced non-headache symptoms in the majority of subjects receiving it: 91% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visits, compared with 33% in the single-blinded placebo visit. Cranial autonomic symptoms were induced by nitroglycerin infusion, 94% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visit, compared with 17% in the single-blinded placebo visit. Conclusion Intravenous weight-adjusted nitroglycerin administration in both episodic cluster headache in bout and chronic cluster headache is effective and reliable in inducing cluster headache attacks, cranial autonomic symptoms and non-headache symptoms. Nitroglycerin administration allows the study of cluster headache attacks in their entirety in a standardised way.BACKGROUNDNitroglycerin administration allows the study of cluster headache attacks in their entirety in a standardised way.A single-blind, placebo-controlled, cross-over study using weight-calculated intravenous nitroglycerin administration at 0.5 µg/kg/min over 20 minutes to study cluster headache attacks, including accompanying non-headache symptoms and cranial autonomic symptoms.METHODSA single-blind, placebo-controlled, cross-over study using weight-calculated intravenous nitroglycerin administration at 0.5 µg/kg/min over 20 minutes to study cluster headache attacks, including accompanying non-headache symptoms and cranial autonomic symptoms.Thirty-three subjects with cluster headache were included in the study; 24 completed all three study visits. Nitroglycerin-induced attacks developed in 26 out of 33 subjects (79%) receiving unblinded nitroglycerin infusion, and in 19 out of 25 subjects (76%) receiving single-blinded nitroglycerin infusion, compared with one out of 24 subjects (4%) receiving single-blinded placebo infusion. Episodic cluster headache subjects had a shorter latency period to a nitroglycerin-induced attack compared to the chronic cluster headache (CCH) subjects (U = 15, z = -2.399, p = 0.016). Sixteen of nineteen episodic cluster headache (mean, 84%; 95% confidence interval, 66-100%) and 11 of 14 chronic cluster headache subjects developed a nitroglycerin-induced attack (79%, 54-100%) following the unblinded nitroglycerin infusion. Following the single-blinded nitroglycerin infusion, eight out of 13 episodic cluster headache (62%, 31-92%) and 11 out of 12 chronic cluster headache (92%, 73-100%) subjects developed nitroglycerin-induced attacks. Nitroglycerin induced non-headache symptoms in the majority of subjects receiving it: 91% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visits, compared with 33% in the single-blinded placebo visit. Cranial autonomic symptoms were induced by nitroglycerin infusion, 94% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visit, compared with 17% in the single-blinded placebo visit.RESULTSThirty-three subjects with cluster headache were included in the study; 24 completed all three study visits. Nitroglycerin-induced attacks developed in 26 out of 33 subjects (79%) receiving unblinded nitroglycerin infusion, and in 19 out of 25 subjects (76%) receiving single-blinded nitroglycerin infusion, compared with one out of 24 subjects (4%) receiving single-blinded placebo infusion. Episodic cluster headache subjects had a shorter latency period to a nitroglycerin-induced attack compared to the chronic cluster headache (CCH) subjects (U = 15, z = -2.399, p = 0.016). Sixteen of nineteen episodic cluster headache (mean, 84%; 95% confidence interval, 66-100%) and 11 of 14 chronic cluster headache subjects developed a nitroglycerin-induced attack (79%, 54-100%) following the unblinded nitroglycerin infusion. Following the single-blinded nitroglycerin infusion, eight out of 13 episodic cluster headache (62%, 31-92%) and 11 out of 12 chronic cluster headache (92%, 73-100%) subjects developed nitroglycerin-induced attacks. Nitroglycerin induced non-headache symptoms in the majority of subjects receiving it: 91% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visits, compared with 33% in the single-blinded placebo visit. Cranial autonomic symptoms were induced by nitroglycerin infusion, 94% in the open unblinded nitroglycerin visit and 84% in the single-blinded nitroglycerin visit, compared with 17% in the single-blinded placebo visit.Intravenous weight-adjusted nitroglycerin administration in both episodic cluster headache in bout and chronic cluster headache is effective and reliable in inducing cluster headache attacks, cranial autonomic symptoms and non-headache symptoms.CONCLUSIONIntravenous weight-adjusted nitroglycerin administration in both episodic cluster headache in bout and chronic cluster headache is effective and reliable in inducing cluster headache attacks, cranial autonomic symptoms and non-headache symptoms. |
Author | Goadsby, Peter J Wei, Diana Y |
Author_xml | – sequence: 1 givenname: Diana Y orcidid: 0000-0003-0644-7172 surname: Wei fullname: Wei, Diana Y organization: Headache Group, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK – sequence: 2 givenname: Peter J orcidid: 0000-0003-3260-5904 surname: Goadsby fullname: Goadsby, Peter J email: peter.goadsby@kcl.ac.uk organization: Department of Neurology, University of California, Los Angeles, CA, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33615843$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UUtP3DAQtiqqskDvPaEcewn4FTu5IFUrCpWQuNAjshx7smuatYPtIO2_r1cLqEWC04zme8zomyN04IMHhL4RfEaIlOeYMUYw5ZR0bSeI_IQWhIu2pl1LD9BiB9c7_BAdpfSAMW4EFl_QIWOCNC1nC3S_DJspwhp8ck9QmdF5Z_RYTWUS8nZyflWFofIux7Aatwai85Xzw5xc2DV2NmCLbE4ZYrUGbbVZQ6Vz1uZPOkGfBz0m-Ppcj9Hvn5d3y-v65vbq1_LHTW0ajHMN0vZUdpg3gxWDhQEEtwI45Z3mphe97lvJJe6Y6Am2nTDCNoZxJrXGmjfsGF3sfae534A14HPUo5qi2-i4VUE79T_i3VqtwpNqKZFtx4vB92eDGB5nSFltXDIwjtpDmJMql1DalpBloZ7-u-t1yUumhYD3BBNDShGGVwrBavc29fZtRSLeSIzLOpeIy7Vu_EhY74VJr0A9hDn6kvP7_L92tqpu |
CitedBy_id | crossref_primary_10_3389_fpain_2024_1373528 crossref_primary_10_1002_brb3_3360 crossref_primary_10_1186_s10194_022_01389_w crossref_primary_10_1016_j_nicl_2021_102920 crossref_primary_10_1177_03331024221133383 crossref_primary_10_1177_25158163241295990 crossref_primary_10_1007_s11910_024_01362_x crossref_primary_10_1038_s41582_021_00477_w crossref_primary_10_1212_WNL_0000000000207240 crossref_primary_10_1212_CON_0000000000001411 crossref_primary_10_1111_head_14111 crossref_primary_10_1055_s_0042_1758043 crossref_primary_10_1007_s11910_022_01225_3 crossref_primary_10_1111_head_14670 crossref_primary_10_1186_s10194_022_01504_x crossref_primary_10_1136_bmj_2020_059577 |
Cites_doi | 10.1111/head.12971 10.1002/jps.2600700923 10.1056/NEJMoa1813440 10.1111/ene.13980 10.1159/000067206 10.1212/WNL.34.10.1292 10.1046/j.1468-2982.1997.1706666.x 10.1093/brain/awy313 10.1016/0002-9149(85)90325-X 10.1177/0333102417744362 10.1111/j.1526-4610.1992.hed3210485.x 10.1046/j.1468-2982.1995.015002094.x 10.1111/j.1526-4610.1982.hed2202069.x 10.1016/0304-3959(94)00097-X 10.1111/j.1460-9568.2006.04742.x 10.1046/j.1468-2982.1990.1002087.x 10.1177/0333102420905321 10.1111/j.1526-4610.1985.hed2502070.x 10.1046/j.1468-2982.2003.00553.x 10.1177/0333102419856607 10.1001/jamaneurol.2018.1675 10.1111/head.12077 10.1016/0006-8993(95)00348-T 10.1016/j.npep.2009.09.002 10.1007/s11916-001-0012-3 10.1093/brain/120.2.283 10.1046/j.1468-2982.1998.1802091.x 10.1001/archneur.1968.00480050057005 10.1016/0304-3959(96)03066-7 10.1001/jama.1941.02820050021005 10.1111/j.1468-2982.2004.00639.x 10.1046/j.1468-2982.2000.00026.x 10.1111/j.1526-4610.2006.00534.x 10.1016/S0140-6736(98)02470-2 10.1177/0333102417726498 10.1212/01.wnl.0000542491.92981.03 10.1046/j.1468-2982.1990.1002071.x 10.1016/0304-3959(89)90067-5 10.1038/sj.bjp.0704842 10.1016/S0031-6997(25)06663-3 10.1111/j.1468-2982.2009.02014.x 10.1111/j.1600-0773.1989.tb00667.x 10.1177/0333102412444012 |
ContentType | Journal Article |
Copyright | International Headache Society 2021 International Headache Society 2021 2021 International Headache Society |
Copyright_xml | – notice: International Headache Society 2021 – notice: International Headache Society 2021 2021 International Headache Society |
DBID | AFRWT AAYXX CITATION NPM 7X8 5PM |
DOI | 10.1177/0333102421989617 |
DatabaseName | Sage Journals GOLD Open Access 2024 CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: AFRWT name: Sage Journals GOLD Open Access 2024 url: http://journals.sagepub.com/ sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2982 |
EndPage | 933 |
ExternalDocumentID | PMC8217894 33615843 10_1177_0333102421989617 10.1177_0333102421989617 |
Genre | Journal Article |
GroupedDBID | --- -TM .2F .2G .3N .GJ .Y3 01A 0R~ 1OC 29B 31S 31T 31Y 31~ 36B 4.4 53G 54M 5GY 5RE 5VS 6PF 8-1 AABMB AABOD AACKU AADUE AAGGD AAHHS AAJIQ AAJOX AAJPV AANSI AAPEO AAQDB AAQXH AARDL AARIX AASGM AAWTL AAXOT AAYTG AAZBJ ABAWC ABAWP ABCCA ABCQN ABDBF ABDWY ABEIX ABFWQ ABHKI ABIVO ABJIS ABJNI ABKRH ABNCE ABPGX ABQKF ABQXT ABRHV ABVFX ABVVC ABYTW ACARO ACCFJ ACDSZ ACDXX ACFMA ACFYK ACGBL ACGFS ACLHI ACNXM ACOFE ACROE ACRPL ACUHS ACXQS ADBBV ADEBD ADEIA ADMPF ADNBR ADNMO ADOGD ADSTG ADTBJ ADUKL ADYCS ADZOD ADZYD ADZZY AECVZ AEEZP AENEX AEQDE AEQLS AERKM AEUHG AEWDL AEXFG AEXNY AFBPY AFCOW AFEBI AFEET AFKBI AFKRG AFRWT AFUIA AFVCE AFWMB AFZJQ AGNHF AGQPQ AHEFC AIGRN AIWBW AJABX AJAOE AJBDE AJEFB AJMMQ AJSCY AJUZI AJXGE ALMA_UNASSIGNED_HOLDINGS ARTOV ASPBG AUTPY AVWKF AYAKG AZFZN B8M B8O B93 BDDNI BFHJK BKSCU BSEHC BYIEH CAG CBRKF CDWPY CFDXU CO8 COF CORYS CQQTX CS3 CUTAK DC- DC. DC0 DC6 DCZOG DD- DD0 DE- DOPDO DU5 D~Y EAD EAP EAS EBC EBD EBS EBX ECV EJD EMB EMK EMOBN ENC EPT ESX F5P FEDTE FZ0 GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HVGLF HZI HZ~ IHE J8X K.F K.J LH4 LW6 N9A O9- OIG OVD P.B P2P Q1R Q7K Q7R Q7X Q82 Q~Q ROL S01 SASJQ SAUOL SCDPB SCNPE SFC SV3 TEORI TUS W99 WYUIH YFH ZGI ZONMY ZPPRI ZRKOI ZSSAH AAEJI AAMMB AAYXX ACHEB AEFGJ AGXDD AIDQK AIDYY CITATION M4V NPM 7X8 5PM |
ID | FETCH-LOGICAL-c500t-e7db279045fd6fdefe64d6e4249a4cb6bab87470936b10d96c6d5c3437aa0a453 |
IEDL.DBID | AFRWT |
ISSN | 0333-1024 1468-2982 |
IngestDate | Thu Aug 21 14:08:54 EDT 2025 Fri Jul 11 01:04:12 EDT 2025 Thu Apr 03 06:57:14 EDT 2025 Tue Aug 05 12:12:23 EDT 2025 Thu Apr 24 23:03:36 EDT 2025 Tue Jun 17 22:26:45 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Cluster headache nitroglycerin nitroglycerin headache chronic cluster headache non-headache symptoms cranial autonomic symptoms episodic cluster headache |
Language | English |
License | This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c500t-e7db279045fd6fdefe64d6e4249a4cb6bab87470936b10d96c6d5c3437aa0a453 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-3260-5904 0000-0003-0644-7172 |
OpenAccessLink | https://journals.sagepub.com/doi/full/10.1177/0333102421989617?utm_source=summon&utm_medium=discovery-provider |
PMID | 33615843 |
PQID | 2492289897 |
PQPubID | 23479 |
PageCount | 21 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8217894 proquest_miscellaneous_2492289897 pubmed_primary_33615843 crossref_primary_10_1177_0333102421989617 crossref_citationtrail_10_1177_0333102421989617 sage_journals_10_1177_0333102421989617 |
PublicationCentury | 2000 |
PublicationDate | 2021-07-01 |
PublicationDateYYYYMMDD | 2021-07-01 |
PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | London, England |
PublicationPlace_xml | – name: London, England – name: England – name: Sage UK: London, England |
PublicationTitle | Cephalalgia |
PublicationTitleAlternate | Cephalalgia |
PublicationYear | 2021 |
Publisher | SAGE Publications |
Publisher_xml | – name: SAGE Publications |
References | Fanciullacci, Alessandri, Sicuteri 1997; 120 Bellamy, Bowen, Russo 2006; 23 Drummond, Lance 1984; 34 Akerman, Williamson, Kaube 2002; 137 Ekbom 1968; 19 Blau, Engel 1998; 18 Moncada, Palmer, Higgs 1991; 43 Bogucki 1990; 10 Peatfield 2001; 5 Gaul, Christmann, Schröder 2012; 32 Leone, Attanasio, Croci 1997; 17 Schurks, Kurth, de Jesus 2006; 46 Strecker, Dux, Messlinger 2002; 39 Vollesen, Snoer, Beske 2018; 75 Goadsby, Dodick, Leone 2019; 381 May, Bahra, Büchel 1998; 352 Torfgard, Ahlner, Axelsson 1989; 64 Sances, Tassorelli, Pucci 2004; 24 Iversen, Olesen, Tfelt-Hansen 1989; 38 Noonan, Benet 1985; 55 Zidverc-Trajkovic, Podgorac, Radojicic 2013; 53 Taga, Russo, Manzoni 2017; 57 McNiff, Yacobi, Young-Chang 1981; 70 Drummond, Anthony 1985; 25 Fanciullacci, Alessandri, Figini 1995; 60 Horton 1941; 116 Peters 1953; 28 Costa, Pucci, Antonaci 2000; 20 Snoer, Lund, Jensen 2019; 26 Tvedskov, Iversen, Olesen 2010; 30 Karsan, Bose, Goadsby 2018; 24 Tassorelli, Joseph 1995; 682 Goadsby, de Coo, Silver 2018; 38 Dahl, Russell, Nyberg-Hansen 1990; 10 Costa, Ravaglia, Sances 2003; 23 Snoer, Lund, Beske 2018; 38 de Coo, Marin, Silberstein 2019; 39 Hsieh, Hannerz, Ingvar 1996; 67 Akerman, Karsan, Bose 2019; 142 Eberhardt, Neeb, Vogel 2009; 43 Olesen, Thomsen, Lassen 1995; 15 Barre 1982; 22 Hannerz, Greitz 1992; 32 Dodick, Goadsby, Lucas 2020; 40 Snoer, Lund, Beske 2018; 91 Karsan N (e_1_3_3_34_2) 2018; 24 e_1_3_3_17_2 e_1_3_3_16_2 (e_1_3_3_29_2) 2013 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_12_2 e_1_3_3_37_2 Peters GA. (e_1_3_3_3_2) 1953; 28 e_1_3_3_15_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_40_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_44_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_21_2 e_1_3_3_42_2 |
References_xml | – volume: 352 start-page: 275 year: 1998 end-page: 278 article-title: Hypothalamic activation in cluster headache attacks publication-title: Lancet – volume: 19 start-page: 487 year: 1968 end-page: 493 article-title: Nitroglycerin as a provocative agent: In cluster headache publication-title: Arch Neurol – volume: 70 start-page: 1054 year: 1981 end-page: 1058 article-title: Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects publication-title: J Pharmaceut Sci – volume: 34 start-page: 1292 year: 1984 end-page: 1298 article-title: Thermographic changes in cluster headache publication-title: Neurology – volume: 5 start-page: 67 year: 2001 end-page: 70 article-title: Migrainous features in cluster headache publication-title: Curr Pain Headache Rep – volume: 142 start-page: 103 year: 2019 end-page: 119 article-title: Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity publication-title: Brain – volume: 43 start-page: 483 year: 2009 end-page: 489 article-title: Glycerol trinitrate facilitates stimulated CGRP release but not gene expression of CGRP or its receptor components in rat trigeminal ganglia publication-title: Neuropeptides – volume: 24 start-page: 996 year: 2018 end-page: 1008 article-title: The migraine premonitory phase publication-title: Continuum – volume: 10 start-page: 71 year: 1990 end-page: 75 article-title: Studies on nitroglycerin and histamine provoked cluster headache attacks publication-title: Cephalalgia – volume: 39 start-page: 967 year: 2019 end-page: 977 article-title: Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis publication-title: Cephalalgia – volume: 38 start-page: 17 year: 1989 end-page: 24 article-title: Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics publication-title: Pain – volume: 18 year: 1998 article-title: Premonitory and prodromal symptoms in cluster headache publication-title: Cephalalgia – volume: 381 start-page: 132 year: 2019 end-page: 141 article-title: Trial of galcanezumab in prevention of episodic cluster headache publication-title: N Engl J Med – volume: 57 start-page: 290 year: 2017 end-page: 297 article-title: Cluster headache with accompanying migraine-like features: A possible clinical phenotype publication-title: Headache – volume: 26 year: 2019 article-title: More precise phenotyping of cluster headache using prospective attack reports publication-title: Eur J Neurol – volume: 22 start-page: 69 year: 1982 end-page: 73 article-title: Cocaine as an abortive agent in cluster headache publication-title: Headache – volume: 38 start-page: 1128 year: 2018 end-page: 1137 article-title: Pre-attack signs and symptoms in cluster headache: Characteristics and time profile publication-title: Cephalalgia – volume: 25 start-page: 70 year: 1985 end-page: 74 article-title: Extracranial vascular responses to sublingual nitroglycerin and oxygen inhalation in cluster headache patients publication-title: Headache – volume: 24 start-page: 110 year: 2004 end-page: 119 article-title: Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches publication-title: Cephalalgia – volume: 60 start-page: 119 year: 1995 end-page: 123 article-title: Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. publication-title: Pain – volume: 55 start-page: 184 year: 1985 end-page: 187 article-title: Incomplete and delayed bioavailability of sublingual nitroglycerin publication-title: American J Cardiol – volume: 137 start-page: 935 year: 2002 end-page: 948 article-title: Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels publication-title: Brit J Pharmacol – volume: 10 start-page: 87 year: 1990 end-page: 94 article-title: Cluster headache: Transcranial Doppler ultrasound and rCBF studies publication-title: Cephalalgia – volume: 30 start-page: 928 year: 2010 end-page: 932 article-title: Nitroglycerin provocation in normal subjects is not a useful human migraine model? publication-title: Cephalalgia – volume: 43 start-page: 109 year: 1991 end-page: 142 article-title: Nitric oxide: Physiology, pathophysiology, and pharmacology publication-title: Pharmacol Rev – volume: 75 start-page: 1187 year: 2018 end-page: 1197 article-title: Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: A randomized clinical trial publication-title: JAMA Neurol – volume: 20 start-page: 85 year: 2000 end-page: 91 article-title: The effect of intranasal cocaine and lidocaine on nitroglycerin-induced attacks in cluster headache publication-title: Cephalalgia – volume: 15 start-page: 94 year: 1995 end-page: 100 article-title: The nitric oxide hypothesis of migraine and other vascular headaches publication-title: Cephalalgia – volume: 32 start-page: 571 year: 2012 end-page: 577 article-title: Differences in clinical characteristics and frequency of accompanying migraine features in episodic and chronic cluster headache publication-title: Cephalalgia – volume: 23 start-page: 2057 year: 2006 end-page: 2066 article-title: Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons publication-title: Eur J Neurosci – volume: 32 start-page: 485 year: 1992 end-page: 488 article-title: MRI of intracranial arteries in nitroglycerin induced cluster headache attacks publication-title: Headache – volume: 17 start-page: 666 year: 1997 end-page: 672 article-title: The M-Chlorophenylpiperazine test in cluster headache: A study on central serotoninergic activity. publication-title: Cephalalgia – volume: 28 start-page: 673 year: 1953 end-page: 686 article-title: Migraine: Diagnosis and treatment with emphasis on the migraine-tension headache, provocative tests and use of rectal suppositories publication-title: Proc Staff Meet Mayo Clin – volume: 67 start-page: 59 year: 1996 end-page: 68 article-title: Right-lateralised central processing for pain of nitroglycerin-induced cluster headache publication-title: Pain – volume: 23 start-page: 407 year: 2003 end-page: 413 article-title: Nitric oxide pathway and response to nitroglycerin in cluster headache patients: Plasma nitrite and citrulline levels publication-title: Cephalalgia – volume: 116 start-page: 377 year: 1941 end-page: 383 article-title: The use of histamine in the treatment of specific types of headaches publication-title: JAMA – volume: 53 start-page: 1464 year: 2013 end-page: 1469 article-title: Migraine-like accompanying features in patients with cluster headache. How important are they? publication-title: Headache – volume: 46 start-page: 1246 year: 2006 end-page: 1254 article-title: Cluster headache: Clinical presentation, lifestyle features, and medical treatment publication-title: Headache – volume: 39 start-page: 489 year: 2002 end-page: 496 article-title: Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow publication-title: J Vasc Res – volume: 91 start-page: e822 year: 2018 end-page: e831 article-title: Cluster headache beyond the pain phase: A prospective study of 500 attacks publication-title: Neurology – volume: 64 start-page: 369 year: 1989 end-page: 372 article-title: Tissue distribution of glyceryl trinitrate and the effect on cGMP levels in rat publication-title: Pharmacol Toxicol – volume: 40 start-page: 62 year: 2020 end-page: 68 article-title: Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment publication-title: Cephalalgia – volume: 38 start-page: 959 year: 2018 end-page: 969 article-title: Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study publication-title: Cephalalgia – volume: 682 start-page: 167 year: 1995 end-page: 181 article-title: Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat publication-title: Brain Res – volume: 120 start-page: 283 year: 1997 end-page: 288 article-title: Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients publication-title: Brain – volume: 28 start-page: 673 year: 1953 ident: e_1_3_3_3_2 article-title: Migraine: Diagnosis and treatment with emphasis on the migraine-tension headache, provocative tests and use of rectal suppositories publication-title: Proc Staff Meet Mayo Clin – ident: e_1_3_3_23_2 doi: 10.1111/head.12971 – ident: e_1_3_3_31_2 doi: 10.1002/jps.2600700923 – ident: e_1_3_3_45_2 doi: 10.1056/NEJMoa1813440 – ident: e_1_3_3_26_2 doi: 10.1111/ene.13980 – ident: e_1_3_3_40_2 doi: 10.1159/000067206 – ident: e_1_3_3_8_2 doi: 10.1212/WNL.34.10.1292 – ident: e_1_3_3_4_2 doi: 10.1046/j.1468-2982.1997.1706666.x – ident: e_1_3_3_37_2 doi: 10.1093/brain/awy313 – ident: e_1_3_3_27_2 doi: 10.1016/0002-9149(85)90325-X – ident: e_1_3_3_46_2 doi: 10.1177/0333102417744362 – ident: e_1_3_3_12_2 doi: 10.1111/j.1526-4610.1992.hed3210485.x – ident: e_1_3_3_30_2 doi: 10.1046/j.1468-2982.1995.015002094.x – ident: e_1_3_3_7_2 doi: 10.1111/j.1526-4610.1982.hed2202069.x – ident: e_1_3_3_13_2 doi: 10.1016/0304-3959(94)00097-X – ident: e_1_3_3_42_2 doi: 10.1111/j.1460-9568.2006.04742.x – ident: e_1_3_3_11_2 doi: 10.1046/j.1468-2982.1990.1002087.x – ident: e_1_3_3_44_2 doi: 10.1177/0333102420905321 – ident: e_1_3_3_9_2 doi: 10.1111/j.1526-4610.1985.hed2502070.x – ident: e_1_3_3_18_2 doi: 10.1046/j.1468-2982.2003.00553.x – ident: e_1_3_3_47_2 doi: 10.1177/0333102419856607 – ident: e_1_3_3_5_2 doi: 10.1001/jamaneurol.2018.1675 – ident: e_1_3_3_22_2 doi: 10.1111/head.12077 – ident: e_1_3_3_38_2 doi: 10.1016/0006-8993(95)00348-T – ident: e_1_3_3_41_2 doi: 10.1016/j.npep.2009.09.002 – ident: e_1_3_3_21_2 doi: 10.1007/s11916-001-0012-3 – ident: e_1_3_3_14_2 doi: 10.1093/brain/120.2.283 – ident: e_1_3_3_20_2 doi: 10.1046/j.1468-2982.1998.1802091.x – ident: e_1_3_3_6_2 doi: 10.1001/archneur.1968.00480050057005 – ident: e_1_3_3_15_2 doi: 10.1016/0304-3959(96)03066-7 – ident: e_1_3_3_2_2 doi: 10.1001/jama.1941.02820050021005 – ident: e_1_3_3_19_2 doi: 10.1111/j.1468-2982.2004.00639.x – ident: e_1_3_3_17_2 doi: 10.1046/j.1468-2982.2000.00026.x – ident: e_1_3_3_35_2 doi: 10.1111/j.1526-4610.2006.00534.x – ident: e_1_3_3_16_2 doi: 10.1016/S0140-6736(98)02470-2 – ident: e_1_3_3_24_2 doi: 10.1177/0333102417726498 – ident: e_1_3_3_25_2 doi: 10.1212/01.wnl.0000542491.92981.03 – ident: e_1_3_3_10_2 doi: 10.1046/j.1468-2982.1990.1002071.x – ident: e_1_3_3_32_2 doi: 10.1016/0304-3959(89)90067-5 – ident: e_1_3_3_43_2 doi: 10.1038/sj.bjp.0704842 – ident: e_1_3_3_28_2 doi: 10.1016/S0031-6997(25)06663-3 – ident: e_1_3_3_33_2 doi: 10.1111/j.1468-2982.2009.02014.x – ident: e_1_3_3_39_2 doi: 10.1111/j.1600-0773.1989.tb00667.x – ident: e_1_3_3_36_2 doi: 10.1177/0333102412444012 – start-page: 629 volume-title: Cephalalgia year: 2013 ident: e_1_3_3_29_2 – volume: 24 start-page: 996 year: 2018 ident: e_1_3_3_34_2 article-title: The migraine premonitory phase publication-title: Continuum |
SSID | ssj0005606 |
Score | 2.4252827 |
Snippet | Background
Nitroglycerin administration allows the study of cluster headache attacks in their entirety in a standardised way.
Methods
A single-blind,... Nitroglycerin administration allows the study of cluster headache attacks in their entirety in a standardised way. A single-blind, placebo-controlled,... Nitroglycerin administration allows the study of cluster headache attacks in their entirety in a standardised way.BACKGROUNDNitroglycerin administration allows... |
SourceID | pubmedcentral proquest pubmed crossref sage |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 913 |
SubjectTerms | Original |
Title | Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks |
URI | https://journals.sagepub.com/doi/full/10.1177/0333102421989617 https://www.ncbi.nlm.nih.gov/pubmed/33615843 https://www.proquest.com/docview/2492289897 https://pubmed.ncbi.nlm.nih.gov/PMC8217894 |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwELZ4SIgLaimPpS0yEkLqId3ErzinClpWCAkOFQguVWTHDosECVqSw_57ZvJYul0VcYsSO3E8M_bY881nQg65k7HX2iBnqA1ELqPARiwKuI-Yc5Jp2WS5Xlyqs2txfitvl0jR58J0Pfj8HWFV0KJmsEbrxt3oYRdkHIacg1uC0cxEJzAH_6irx7Td7e4P1cA7GJ6uHzGynSEechr02W3LZJXFSoIhrx6Pft9cvYJCVNhGNzkitph4DWwufHN-IlvwThdBln8hxZrJa_SBbHReJz1u1eQjWfLFJlm76OLqn8gfHBYmftyi2WmfLkkRAFZWU8ypomVOwfwn5d3DNMOcQQq6WeNeG1w4UBAH1WqkXaAwvjvkiaamqjCFf4tcj06vfp4F3cELQSbDsAp87CyLE_D2cqdy53OvhFNewFLNiMwqa6yGZUiYcGWj0CUqU05mXPDYmNAIybfJSlEWfpfQKM-dTHKdaGmEh6oMtAC8FFyWZ9aKARn2vZhmHSs5Ho7xkEY9Efk__T4g32Y1nlpGjjfKHvSCScFsMBZiCl_WzykSJTI8OhPK7LSCmr2Nc3DztOADEs-JcFYAKbnnnxT344aaW8MKTyfwV0co7LTX5v82cO-9BT-TdYZomgYo_IWsVJPafwV3qLL7oMMnv05G-50uvwBOmwXm |
linkProvider | SAGE Publications |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwEB7RRaJcEH2y9GWkCqmHtEn8iHNEqKulZTmgRXCpIjt2SiWUoCV74N8zk8fCsiriFim25Xg8nnHmm28AvnInE6-1Ic5QG4hCRoGN4ijgPoqdk7GWTZbr5ESNz8SvC3nxoNRXt4I33wlWhTNqDuuFdhNTEufokVAgM9Upmt8XsC7IaA1g_WB0ej69x3eosA1UcgJfxeI-RrkyxrJNWnE0V_GSD0BfjR0abcNW50Cyg1bir2DNl69hY9KFyN_AH9Lwmb9sgemsz3xkhOWq6ltKj2JVwVCTZ9Xfq9uc0v8YbrM5_TbDB4eydthtTgwKDI9qR5TPzNQ1ZeO_hbPRz-nhOOhqKAS5DMM68ImzcZKi41Y4VThfeCWc8gJvXUbkVlljNd4owpQrG4UuVblyMueCJ8aERkj-DgZlVfodYFFROJkWOtXSCI9dYxQoOhx0w86tFUP40a9ilncE41Tn4iqLek7xR-s-hG-LHtctucYTbfd6wWSoARTWMKWv5jcZcR7GVAUT27xvBbUYjXP02LTgQ0iWRLhoQOzay2_Kf5cNy7bGy5pO8av2SdhZvzH_O8Hd5zb8Ai_H08lxdnx08vsDbMYEkmnwvx9hUM_m_hN6ObX93O3nOzGj8c4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwEB61i4R6qQr0sW0BV0KVekg3iR9xjqiwog8QqkDlUkV2bJdKKEFL9sC_70weC9sVVW-RYluOx-OZyXzzGWCPO5l5rQ1xhtpIBJlENkmTiPskdU6mWrZVrscn6uhcfLmQFz02h2ph-hW8-UiwKpxRe1iTdl-7MOlzjJOYc_RKKJmZ6xxN8GNYEwJN4wjW9qfff5zdYTxU3CUrOQGwUnGXp1wZY9kurTibq5jJe8Cv1hZNn8HT3olk-53UN-CRrzZh_bhPk2_BT9Lymb_swOlsqH5khOeqm1sqkWJ1YKjNs_rX1W1JJYAMt9qcfp3hg0N5O-w2JxYFhse1I9pnZpqGKvKfw_n08OzTUdTfoxCVMo6byGfOplmOzltwKjgfvBJOeYGRlxGlVdZYjVFFnHNlk9jlqlROllzwzJjYCMlfwKiqK_8KWBKCk3nQuZZGeOyaolDR6aAou7RWjGEyrGJR9iTjdNfFVZEMvOJ_rfsYPix6XHcEG_9o-24QTIFaQKkNU_l6flMQ72FKN2Fim5edoBajcY5emxZ8DNmSCBcNiGF7-U31-7Jl2tYYsOkcv-o9CbsYNueDE3z9vw13Yf30YFp8-3zy9Q08SQkn00KA38Komc39Njo6jd3pt_Mf2Bvy3g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+clinical+phenotyping+of+nitroglycerin+infusion+induced+cluster+headache+attacks&rft.jtitle=Cephalalgia&rft.au=Wei%2C+Diana+Y&rft.au=Goadsby%2C+Peter+J&rft.date=2021-07-01&rft.issn=1468-2982&rft.eissn=1468-2982&rft.volume=41&rft.issue=8&rft.spage=913&rft_id=info:doi/10.1177%2F0333102421989617&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0333-1024&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0333-1024&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0333-1024&client=summon |